中国中西医结合杂志
中國中西醫結閤雜誌
중국중서의결합잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2001年
3期
165-167
,共3页
程剑华%常纲%吴万垠%刘伟胜%杨志钢%孟凡喆%徐凯%李柳宁%朱迪盈%陈春泳%罗海英
程劍華%常綱%吳萬垠%劉偉勝%楊誌鋼%孟凡喆%徐凱%李柳寧%硃迪盈%陳春泳%囉海英
정검화%상강%오만은%류위성%양지강%맹범철%서개%리류저%주적영%진춘영%라해영
莪术油%肝动脉灌注栓塞%原发性肝癌
莪術油%肝動脈灌註栓塞%原髮性肝癌
아술유%간동맥관주전새%원발성간암
目的：评价莪术油肝动脉灌注栓塞治疗原发性肝癌的疗效、毒副作用及应用前景。方法：用莪术油1～3ml经动脉插管至肝动脉灌注栓塞治疗原发性肝癌32例，与同期用化疗药灌注栓塞治疗的32例作对照观察。两组均按辨证施治同时服用中药。结果：治疗组CR1例，PR13例，总有效率为43.75%(14/32)；甲胎球蛋白(AFP)转阴7例，滴度下降7例。化疗组PR10例，有效率为31.25%(10/32)；AFP转阴5例，滴度下降2例，两组疗效比较差异无显著性(P＞0.05)。治疗后出现灌注栓塞综合征(发热、腹痛、呕吐等)两组相似；但治疗组无明显骨髓抑制现象，两组比较差异有显著性(P＜0.01或P＜0.05)。治疗组平均生存期11.5个月，中位生存期10个月；1、2、3年生存率分别为37.5%(12/32)、13.3%(4/30)、6.9%(2/29)。化疗组平均生存期7.25个月，中位生存期6个月；1、2、3年生存率分别为15.6%(5/32)、3.2%(1/31)、0。治疗组平均生存期、中位生存期、1年生存率均明显优于化疗组(P＜0.05)。结论：莪术油肝动脉灌注栓塞治疗原发性肝癌疗效与化疗药相似，但生存时间和骨髓抑制明显优于化疗药。
目的：評價莪術油肝動脈灌註栓塞治療原髮性肝癌的療效、毒副作用及應用前景。方法：用莪術油1～3ml經動脈插管至肝動脈灌註栓塞治療原髮性肝癌32例，與同期用化療藥灌註栓塞治療的32例作對照觀察。兩組均按辨證施治同時服用中藥。結果：治療組CR1例，PR13例，總有效率為43.75%(14/32)；甲胎毬蛋白(AFP)轉陰7例，滴度下降7例。化療組PR10例，有效率為31.25%(10/32)；AFP轉陰5例，滴度下降2例，兩組療效比較差異無顯著性(P＞0.05)。治療後齣現灌註栓塞綜閤徵(髮熱、腹痛、嘔吐等)兩組相似；但治療組無明顯骨髓抑製現象，兩組比較差異有顯著性(P＜0.01或P＜0.05)。治療組平均生存期11.5箇月，中位生存期10箇月；1、2、3年生存率分彆為37.5%(12/32)、13.3%(4/30)、6.9%(2/29)。化療組平均生存期7.25箇月，中位生存期6箇月；1、2、3年生存率分彆為15.6%(5/32)、3.2%(1/31)、0。治療組平均生存期、中位生存期、1年生存率均明顯優于化療組(P＜0.05)。結論：莪術油肝動脈灌註栓塞治療原髮性肝癌療效與化療藥相似，但生存時間和骨髓抑製明顯優于化療藥。
목적：평개아술유간동맥관주전새치료원발성간암적료효、독부작용급응용전경。방법：용아술유1～3ml경동맥삽관지간동맥관주전새치료원발성간암32례，여동기용화료약관주전새치료적32례작대조관찰。량조균안변증시치동시복용중약。결과：치료조CR1례，PR13례，총유효솔위43.75%(14/32)；갑태구단백(AFP)전음7례，적도하강7례。화료조PR10례，유효솔위31.25%(10/32)；AFP전음5례，적도하강2례，량조료효비교차이무현저성(P＞0.05)。치료후출현관주전새종합정(발열、복통、구토등)량조상사；단치료조무명현골수억제현상，량조비교차이유현저성(P＜0.01혹P＜0.05)。치료조평균생존기11.5개월，중위생존기10개월；1、2、3년생존솔분별위37.5%(12/32)、13.3%(4/30)、6.9%(2/29)。화료조평균생존기7.25개월，중위생존기6개월；1、2、3년생존솔분별위15.6%(5/32)、3.2%(1/31)、0。치료조평균생존기、중위생존기、1년생존솔균명현우우화료조(P＜0.05)。결론：아술유간동맥관주전새치료원발성간암료효여화료약상사，단생존시간화골수억제명현우우화료약。
Objective: To evaluate the effectiveness, toxicity andprospective application of hepatic arterial infusion (HAI) with Embolized Curcuma Aromatic oil (CAO) in treating primary liver cancer (PLC). Methods: In the treated group, 32 patients with PLC were treated by HAI with 1～3 ml of embolized CAO and oral administration of Chinese herbal medicine. In the control group, 32 patients with PLC were treated with transcatheter artery chemoembolization (TACE). Results: In the treated group, one patient attained complete remission (CR) and 13 partial remission (PR), the total effective rate being 43.75%. The level of alpha fetal protein (AFP) turned to normal range in 7 cases and decreased in other 7. In the control group, 10 obtained PR and the total effective rate being 31.25%, AFP level turned to normal in 5 and decreased in 2. There was no statistical significance between the two groups. The incidences of post-embolism syndrome, such as fever, abdominal pain and vomiting were similar between the two groups but no myelosuppression occurred in the treated group with significant difference (P＜0.01) as comparing with that in the control group. The mean survival time, median survival time, 1-, 2- and 3-year survival rate in the treated group was 11.5 months, 10 months, 37.5%, 13.3% and 6.9% respectively, while in the control group was 7.25 months, 6 months, 15.6%, 3.2% and 0 respectively. The treated group was better in mean survival time, median survival time and 1-year survival rate than that of the control group (P＜0.05). Conclusion: HAI with embolized CAO showed a similar favorite effect in treating PLC as that of TACE, but superior than TACE with longer survival time and milder myelosuppression.
